The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Recent genetic findings in schizophrenia and their therapeutic relevance
Open accessAbstract
Over 100 loci are now associated with schizophrenia risk as identified by single nucleotide polymorphisms (SNPs) in genome-wide association studies. These findings mean that ‘genes for schizophrenia’ have unquestionably been found. However, many questions remain unanswered, including several which affect their therapeutic significance. The SNPs individually have minor effects, and even cumulatively explain only a modest fraction of the genetic predisposition. The remainder likely results from many more loci, from rare variants, and from gene–gene and gene–environment interactions. The risk SNPs are almost all non-coding, meaning that their biological significance is unclear; probably their effects are mediated via an influence on gene regulation, and emerging evidence suggests that some key molecular events occur during early brain development. The loci include novel genes of unknown function as well as genes and pathways previously implicated in the pathophysiology of schizophrenia, e.g. NMDA receptor signalling. Genes in the latter category have the clearer therapeutic potential, although even this will be a challenging process because of the many complexities concerning the genetic architecture and mediating mechanisms. This review summarises recent schizophrenia genetic findings and some key issues they raise, particularly with regard to their implications for identifying and validating novel drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577 · cited 1×
“Compared with schizophrenia-associated SNPs, each CNV is penetrant (Kirov et al., 2014) and confers a significantly increased risk of illness (odds ratios for several CNVs exceed 8), but each CNV is extremely rare, except for hemideletion of 22q11 (velocardiofacial syndrome; Schneider et al., 2014).”
BackgroundCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821 · cited 3×
“GWAS studies have confirmed that the MHC locus on chromosome 6, which encodes HLA and other immune genes (as well as some genes not related to immune function), is associated with the disorder (Corvin and Morris, 2014; McGuffin and Power, 2013; Purcell et al., 2009; Schizophrenia Working Group of the Psychiatric Genom…”
BackgroundResultSystematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716 · cited 2×
“than one gene; a SNP can regulate expression of genes either upstream or downstream within – or outside – the locus; and SNPs can impact on non-protein-coding genes (or unknown genes) as well as annotated proteincoding genes (Maurano et al., 2012).”
Background(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
Paoletti, P., Bellone, C., & Zhou, Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3504 · Cited by 2,523
Schizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studies
Sullivan, P. F., Kendler, K. S., & Neale, M. C. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1187 · Cited by 2,356 · cited 1×
“Estimates of heritability range from ~65–80% (Lichtenstein et al., 2009; Sullivan et al., 2003).”
Genetics of rheumatoid arthritis contributes to biology and drug discovery
the RACI consortium, Okada, Y., the GARNET consortium, Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., et al. (2014) · Nature · doi:10.1038/nature12873 · Cited by 2,310
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) · Nature Genetics · doi:10.1038/ng.2711 · Cited by 2,263
Lichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., & Hultman, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60072-6 · Cited by 2,125
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Self-citationThe emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 2×
“pathway regulating cellular growth and activity (Mei and Nave, 2014; Vanhaesebroeck et al., 2010; Zheng et al., 2012).”
BackgroundAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 2×
“…neurodevelopmental (e.g. Rett syndrome) disorders for which the causal genes and the mutations within them have been known for well over a decade, and despite considerable advances in understanding their molecular pathogenesis (Gadalla et al., 2011; Huang and Mucke, 2012; Ross and Tabrizi, 2011).”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 2×
“A notable convergence is upon NMDA receptor (NMDAR) signalling, providing a genetic complement to, and corroboration of, the prominent pre-existing hypothesis that NMDAR hypofunction (and glutamate synaptic function more generally) is important in the pathophysiology of schizophrenia (Coyle et al., 2003; Frohlich and…”
BackgroundDe novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
A polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385 · cited 7×
“These genes also contain an excess of rare variants in schizophrenia (Purcell et al., 2014).”
BackgroundInfluentialRare and common variants: twenty arguments
Gibson, G. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3118 · Cited by 1,278 · cited 2×
“The existing findings account for only a minority of the heritability of schizophrenia, and there are various explanations for what accounts for the rest (Gibson, 2012; Lee et al., 2011; Manolio et al., 2009).”
BackgroundGenetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177 · cited 2×
“6) The initial GWAS studies, including Ripke et al. (2013), failed to replicate convincingly any of the genes which had been identified from the pre-GWAS era (i.e. from ‘candidate gene’ approaches), even the seemingly robust findings (Allen et al., 2008; Sullivan et al., 2012).”
BackgroundIdentification of loci associated with schizophrenia by genome-wide association and follow-up
Molecular Genetics of Schizophrenia Collaboration, O'Donovan, M. C., Craddock, N., Norton, N., Williams, H., Peirce, T., Moskvina, V., Nikolov, I., Hamshere, M., Carroll, L., et al. (2008) · Nature Genetics · doi:10.1038/ng.201 · Cited by 1,070
Estimating Missing Heritability for Disease from Genome-wide Association Studies
Lee, S. H., Wray, N. R., Goddard, M. E., & Visscher, P. M. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.02.002 · Cited by 1,064 · cited 2×
“The existing findings account for only a minority of the heritability of schizophrenia, and there are various explanations for what accounts for the rest (Gibson, 2012; Lee et al., 2011; Manolio et al., 2009).”
BackgroundMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia
Mei, L., & Xiong, W.-C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2392 · Cited by 1,030 · cited 1×
“Here, the main findings and themes to emerge from the recent genomic studies of schizophrenia are briefly summarised, before considering their therapeutic implications in terms of target discovery and validation.”
BackgroundCNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics
Malhotra, D., & Sebat, J. (2012) · Cell · doi:10.1016/j.cell.2012.02.039 · Cited by 854
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844 · cited 2×
“NMDAR-related and postsynaptic signalling complex genes are over-represented amongst schizophrenia-associated CNVs (Kirov et al., 2012) and are also enriched for rare variants (Fromer et al.”
BackgroundBeyond GWASs: Illuminating the Dark Road from Association to Function
Edwards, S. L., Beesley, J., French, J. D., & Dunning, A. M. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.10.012 · Cited by 784
Schneider, M., Debbané, M., Bassett, A. S., Chow, E. W. C., Fung, W. L. A., van den Bree, M. B. M., Owen, M., Murphy, K. C., Niarchou, M., Kates, W. R., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070864 · Cited by 779 · cited 2×
“Compared with schizophrenia-associated SNPs, each CNV is penetrant (Kirov et al., 2014) and confers a significantly increased risk of illness (odds ratios for several CNVs exceed 8), but each CNV is extremely rare, except for hemideletion of 22q11 (velocardiofacial syndrome; Schneider et al., 2014).”
BackgroundImmune involvement in schizophrenia and autism: Etiology, pathology and animal models
Patterson, P. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.016 · Cited by 766
Validating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712 · cited 19×
“These findings, an illustration of genetic pleiotropy (Solovieff et al., 2013), suggest that the clinical overlap between these disorders arises at least partly from a shared genetic predisposition (Cross Disorder Group of the Psychiatric Genomics Consortium, 2013b).”
BackgroundInfluentialGulsuner, S., Walsh, T., Watts, A. C., Lee, M. K., Thornton, A. M., Casadei, S., Rippey, C., Shahin, H., Braff, D., Cadenhead, K. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.049 · Cited by 536 · cited 3×
“Both act as risk factors; there are no confirmed causal mutations, nor families in which schizophrenia segregates in a Mendelian fashion.”
BackgroundAnalysis of copy number variations at 15 schizophrenia-associated loci
Rees, E., Walters, J. T. R., Georgieva, L., Isles, A. R., Chambert, K. D., Richards, A. L., Mahoney-Davies, G., Legge, S. E., Moran, J. L., McCarroll, S. A., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.131052 · Cited by 443
De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia
Xu, B., Ionita-Laza, I., Roos, J. L., Boone, B., Woodrick, S., Sun, Y., Levy, S., Gogos, J. A., & Karayiorgou, M. (2012) · Nature Genetics · doi:10.1038/ng.2446 · Cited by 442 · cited 1×
“Similarly, genes predominantly expressed in fetal brain are less appealing as drug targets, other things being equal, than those abundantly expressed throughout adulthood (see Gulsuner et al., 2013; Xu et al., 2012).”
BackgroundNeural Mechanisms of a Genome-Wide Supported Psychosis Variant
Esslinger, C., Walter, H., Kirsch, P., Erk, S., Schnell, K., Arnold, C., Haddad, L., Mier, D., Opitz von Boberfeld, C., Raab, K., et al. (2009) · Science · doi:10.1126/science.1167768 · Cited by 400
The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay
Kirov, G., Rees, E., Walters, J. T. R., Escott-Price, V., Georgieva, L., Richards, A. L., Chambert, K. D., Davies, G., Legge, S. E., Moran, J. L., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.022 · Cited by 368 · cited 2×
“Compared with schizophrenia-associated SNPs, each CNV is penetrant (Kirov et al., 2014) and confers a significantly increased risk of illness (odds ratios for several CNVs exceed 8), but each CNV is extremely rare, except for hemideletion of 22q11 (velocardiofacial syndrome; Schneider et al., 2014).”
BackgroundHigh frequencies of de novo CNVs in bipolar disorder and schizophrenia
Malhotra, D., McCarthy, S., Michaelson, J. J., Vacic, V., Burdick, K. E., Yoon, S., Cichon, S., Corvin, A., Gary, S., Gershon, E. S., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.11.007 · Cited by 325 · cited 2×
“It is thus notable that schizophrenia genes are also enriched for ARC genes (Fromer et al., 2014; Glessner et al., 2010; Lips et al., 2012; Malhotra et al., 2011; Purcell et al., 2014) and for those involved in other aspects of synaptic transmission (Kenny et al., 2014; Lips et al., 2012; Owen et…”
BackgroundReviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease
Bhat, S., Dao, D. T., Terrillion, C. E., Arad, M., Smith, R. J., Soldatov, N. M., & Gould, T. D. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.001 · Cited by 271
Synapse elimination and learning rules co-regulated by MHC class I H2-Db
Lee, H., Brott, B. K., Kirkby, L. A., Adelson, J. D., Cheng, S., Feller, M. B., Datwani, A., & Shatz, C. J. (2014) · Nature · doi:10.1038/nature13154 · Cited by 228
Transcriptome-wide Discovery of microRNA Binding Sites in Human Brain
Boudreau, R. L., Jiang, P., Gilmore, B. L., Spengler, R. M., Tirabassi, R., Nelson, J. A., Ross, C. A., Xing, Y., & Davidson, B. L. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.062 · Cited by 217 · cited 2×
“…bioinformatically) are also GWAS schizophrenia genes (including TCF4, ZNF804A, and CACNA1C; Kim et al., 2012; Kwon et al., 2013; Wright et al., 2013; see also Boudreau et al., 2014), suggesting that there may be functional impairment of a network of MIR137-regulated genes in schizophrenia.”
BackgroundBalu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304308110 · Cited by 217 · cited 1×
“Here, the main findings and themes to emerge from the recent genomic studies of schizophrenia are briefly summarised, before considering their therapeutic implications in terms of target discovery and validation.”
BackgroundDiverse types of genetic variation converge on functional gene networks involved in schizophrenia
Gilman, S. R., Chang, J., Xu, B., Bawa, T. S., Gogos, J. A., Karayiorgou, M., & Vitkup, D. (2012) · Nature Neuroscience · doi:10.1038/nn.3261 · Cited by 200 · cited 2×
“Exome sequencing (in which the expressed regions of each gene are sequenced in their entirety) is revealing a spectrum of schizophrenia-associated genetic variants (Gilman et al., 2012; Gulsuner et al., 2013), as there is with other psychiatric disorders (Visscher et al., 2012).”
BackgroundValidation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C and TCF4 as miR-137 targets
Kwon, E., Wang, W., & Tsai, L.-H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.170 · Cited by 200
Grozeva, D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.25 · Cited by 192 · cited 1×
“Like SNPs, the schizophrenia-associated CNVs do not show diagnostic specificity, also conferring risk of autism and learning disability (Malhotra and Sebat, 2012), though perhaps not bipolar disorder (Grozeva et al., 2010).”
BackgroundGROUP investigators, Børglum, A. D., Demontis, D., Grove, J., Pallesen, J., Hollegaard, M. V., Pedersen, C. B., Hedemand, A., Mattheisen, M., Uitterlinden, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.2 · Cited by 186
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia
the International Schizophrenia Consortium, Lips, E. S., Cornelisse, L. N., Toonen, R. F., Min, J. L., Hultman, C. M., Holmans, P. A., O'Donovan, M. C., Purcell, S. M., Smit, A. B., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.117 · Cited by 167 · cited 4×
“It is thus notable that schizophrenia genes are also enriched for ARC genes (Fromer et al., 2014; Glessner et al., 2010; Lips et al., 2012; Malhotra et al., 2011; Purcell et al., 2014) and for those involved in other aspects of synaptic transmission (Kenny et al., 2014; Lips et al., 2012; Owen et…”
BackgroundInfluentialLaw, A. J., Wang, Y., Sei, Y., O’Donnell, P., Piantadosi, P., Papaleo, F., Straub, R. E., Huang, W., Thomas, C. J., Vakkalanka, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206118109 · Cited by 147
Self-citationMHC class I modulates NMDA receptor function and AMPA receptor trafficking
Fourgeaud, L., Davenport, C. M., Tyler, C. M., Cheng, T. T., Spencer, M. B., & Boulanger, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914064107 · Cited by 89
Cited by
Lieberman, J. A., Girgis, R. R., Brucato, G., Moore, H., Provenzano, F., Kegeles, L., Javitt, D., Kantrowitz, J., Wall, M. M., Corcoran, C. M., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.249 · Cited by 376
Hippocampal-Prefrontal Interactions in Cognition, Behavior and Psychiatric Disease
Sigurdsson, T., & Duvarci, S. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00190 · Cited by 309
Human gene and disease associations for clinical‐genomics and precision medicine research
Ahmed, Z., Zeeshan, S., Mendhe, D., & Dong, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.28 · Cited by 291
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Rahman, T., Zavitsanou, K., Purves-Tyson, T., Harms, L. R., Meehan, C., Schall, U., Todd, J., Hodgson, D. M., Michie, P. T., & Weickert, C. S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00077 · Cited by 39
“The clear and robust increases in NMDAR2A, whose gene has been recently linked to the increased risk of schizophrenia (62), suggest a possible point of convergence between genetic and environmental risk (maternal infection) factors in schizophrenia.”
Background
Metadata
- Authors
- Harrison, P. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-10-14
- Volume
- 29
- Issue
- 2
- Pages
- 85-96
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2039547082
- Cited by
- 183
- References
- 49
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.